Continuity in Care®: Best Practices in Immunoglobulin Therapy—Improving Quality of Life for Patients With Primary Immunodeficiency

Release Date: December 22, 2021
Expiration Date: December 22, 2022

Activity Overview

This video-based program is designed to help health care professionals explore treatment options for patients with primary immunodeficiency (PI) through a unique perspective: putting the patient voice front and center. A patient will lend her expertise to this program by sharing her journey living with PI. This online activity focuses on diagnostic considerations, patient- and disease-related factors that affect the use of intravenous (IVIg) or subcutaneous immunoglobulin (SCIg), and ways to individualize each patient’s treatment using a multidisciplinary team.
 

This activity is supported by educational grants from CSL Behring, LLC, and Grifols.
 

Target Audience

These activities are intended for an audience of immunologists, infusion nurses, pediatricians, nurse practitioners, physician assistants, and pharmacists involved in the dispensing and administration of immunoglobulin replacement therapy (IgG) for patients with PI.
 

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Discuss the disease burden of PI as related to quality of life (QOL)
• Select an optimal route of administration for immunoglobulin therapy based on clinical presentation and goals of therapy
• Analyze the efficacy and safety data regarding the use of subcutaneous immunoglobulin SCIg products in patients with PI
• Describe best practices for optimal administration of SCIg in the management of PI
• Identify appropriate infusion devices and ancillary supplies that align with patient preferences

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 
 

Chair

Bob Geng, MD
Associate Clinical Voluntary Professor
UC San Diego School of Medicine
President, San Diego Allergy Society
Co-Director, AAFA-Rady Children’s Hospital Severe Asthma Program
Allergy/Immunology Director of the Multidisciplinary Atopic Dermatitis Program
San Diego, CA


 

Faculty

Elizabeth Duruz, RPh, CSP, IgCP
Regional Clinical Pharmacist
Optum
Atlanta, GA
 

Disclosures: Elizabeth Duruz, RPh, CSP, IgCP, has no relevant financial relationships with ineligible companies.
 

Kristin Epland, MSN, FNP-C
Nurse Practitioner
Nurse Advisory Committee
Immune Deficiency Foundation
Minneapolis, MN
 

Disclosures: Consultant: Takeda Pharmaceutical Company; Speaker’s Bureau: Takeda Pharmaceutical Company.

Disclosures: Joan Schwarz, has no relevant financial relationships with ineligible companies.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.